The compelling investment case for GreenStar Biosciences (CSE:GSTR | OTC:GTSIF)

By Richard Mason


Entering a second market can often lead to a positive step-change in performance for a well-run growth company.

Entering a second market can often lead to a positive step-change in performance for a well-run growth company.

It diversifies risk and presents the market with an alternative stream of news flow.

If handled right, such a move can unleash incredible returns.

It can reinvigorate the narrative and set the share price on a new upward trajectory.

Much depends on the quality of the team leading the business, yet other factors play a significant role too.

What financial state is the company in?

What sector is it planning to enter?

Does it have the right people to get the most out of the new operating unit?

How much of a realizable opportunity is this?

With so many moving parts to consider, many investors can adopt a ‘wait and see’ approach.

They prefer to let things play out before buying into the revised vision.

This is usually a big mistake.

After all, the market rewards anticipation. Not hesitancy.

The trick for the smart investor is to identify those features in a stock that can act as catalysts for future growth and maximize its chances of success.

GreenStar Biosciences (CSE:GSTR | OTC:GTSIF) is a perfect case in point.

A month before the lockdown, this company appointed a top-level CEO, Tom Baird, who immediately put into play an extremely ambitious, ‘transformational’ strategy leveraging the capabilities of an exceptional team.

Under the most difficult circumstances, Baird and his team pushed ahead regardless and just delivered an extremely important milestone.

He’s closed on the acquisition of Eleusian, which brings GreenStar (CSE:GSTR | OTC:GTSIF) into the ‘transformational medicine’ space alongside its thriving retail cannabis business.

The company is now about to embark on a period of intense activity that could see it deliver a number of substantial value events across its asset base.

The second half of 2020 promises to be an exhilarating ride, and this is certainly one stock well worth researching.


For a deep dive into GreenStar Biosciences’ (CSE:GSTR | OTC:GTSIF) transformational strategy download our EXCLUSIVE REPORT

Transformational medicines’ represent the next great frontier in medical science.

Using psychedelic compounds (such as cannabinoids, psilocybin or MDMA) to treat a wide variety of mental health conditions, transformational medicines have immense potential to revolutionize healing of the mind.

This obviously has global reach, and hundreds of millions of research dollars are starting to flow into the space.

Unsurprisingly, the sector is expected to become extremely hot over the next 18 months.

The eventual winners will be those companies that can combine rigorous scientific discipline with commercial prowess while managing complex project management.

Under Baird’s leadership, GreenStar (CSE:GSTR | OTC:GTSIF) fits this profile.

In a major development on July 27, the company completed the acquisition of Eleusian Biosciences.

Already recognized as one of the most sophisticated developers of transformational medicines, Eleusian brings with it an extremely talented team of researchers and a pipeline of potential blockbuster products.

Through its strategic research partnership with the University of Miami’s Miller School of Medicine, Eleusian had secured for itself a strong position.

The Miller School of Medicine is widely respected for its first-rate research on Schedule I controlled substances. It is one of the few research institutions to have been awarded a license by the U.S. Drug Enforcement Agency for this purpose.

Working with this school is a real accolade for GreenStar (CSE:GSTR | OTC:GTSIF), and reflects the quality of the people it has recruited through its acquisition.

Eleusian’s Chief Science Officer, Maghsoud Dariani (who is now a key member of GreenStar’s (CSE:GSTR | OTC:GTSIF) executive team) has an incredible track record in lucrative drug discovery.

He’s already overseen projects in his career that achieved FDA approval, including one for the development of Focalin. Sold by Novartis, one of the world’s leading pharmaceutical firms, Focalin is a derivative of Ritalin, the medication used to treat ADHD.

At Eleusian, Dariani brought all this experience to bear. His team has already filed for three provisional patents, which will now be taken forward under the GreenStar (CSE:GSTR | OTC:GTSIF) banner.

Two of these patents are for novel treatments for concussion-induced post-traumatic stress disorder (separately using psilocybin and MDMA), while the third is for an innovative device called a “nasal mist transducer”. This allows precise doses of medication to be sprayed into the nasal cavity and rapidly enter the bloodstream.

Over the next 12 months, GreenStar (CSE:GSTR | OTC:GTSIF) is on course to deliver a deluge of news flow as it advances its patents and recruits a strategic partner to begin precision engineering work on the nasal mist transducer.

What’s more, the Miller research partnership opens the door to further ground-breaking research, and it is quite conceivable GreenStar (CSE:GSTR | OTC:GTSIF) will add to its I.P. portfolio with more patent applications.

Read our SPECIAL REPORT to learn how GreenStar’s (CSE:GSTR | OTC:GTSIF) “Cowlitz Option” could trigger a transformational value event this year

While the move into transformational medicines is very much GreenStar’s (CSE:GSTR | OTC:GTSIF) future, the company’s existing business could still yield a massive return for investors in the near-term.

The company owns an exclusive option to acquire Cowlitz County Cannabis Cultivation.

Cowlitz is an established processor, marketer, and vendor of recreational cannabis in Washington State, one of the largest U.S. domestic markets. State-wide sales are expected to hit a record US$2.3 billion in 2020.

In its most recent figures, released on July 29, Cowlitz reported a 24% quarter-on-quarter increase in revenue to US$6.6 million in gross sales.

GreenStar (CSE:GSTR | OTC:GTSIF) believes Cowlitz is on course to deliver in excess of $19 million revenue in the full year, but this value is barely recognized on the company’s balance sheet.

Current restrictions on the foreign ownership of Washington State recreational cannabis vendors mean GreenStar (CSE:GSTR | OTC:GTSIF) has not been able yet to exercise its option.

However, this could all be about to change with a recent legal challenge.

In July 2020, an Idaho businessman launched an action against Washington State’s Liquor and Cannabis Board.

The case argues that the law prohibiting individuals and businesses that do not reside in the State from investing in local marijuana businesses is discriminatory and unconstitutional.

Although this is in its early days, existing precedent paints an extremely positive picture.

Earlier in 2020, the state of Maine declined to defend the constitutionality of its residency requirement following a very similar challenge to that in Washington State.

The residency requirement was so patently unconstitutional that Maine announced it would cease enforcing the residency requirement after a complaint was filed but before the court heard a single motion in the case.”

petition for declaratory judgment in the matter of Todd Brinkmeyer v Washington State Liquor and Cannabis Board

For GreenStar (CSE:GSTR | OTC:GTSIF) and its shareholders, the implications could be massive.

Right at the point the company is venturing out into transformational medicines, the Washing State legal challenge could enable it to realize a substantial gain from the Cowlitz Option.

The timing would be perfect.

GreenStar Biosciences (CSE:GSTR | OTC:GTSIF) has 12 months of thrilling news flow lined up – it all starts now – discover how in our SPECIAL REPORT



This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Greenstar Biosciences Corp to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred thousand USD to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production of this piece by the company or companies mentioned above.


Author: Richard Mason

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter